

Enterprise name **RĪGAS FARMACEITISKĀ FABRIKA**

Registration No 

0	0	0	3	0	0	0	7	6
---	---	---	---	---	---	---	---	---

Registration No of tax-payer 

4	0	0	0	3	0	0	0	7	6	5
---	---	---	---	---	---	---	---	---	---	---

Address Rīga , Dunties 16/22

Phone 67355550 , 67355548 Fax 67391790

The basic kind of activity: manufacturing of medicines

Unit: LVL and EUR

# **B A L A N C E**

for the period ended 31.March 2010

# a/s "Rīgas Farmaceutiskā Fabrika"

reg. No 40003000765  
Rīga, Dunties iela 16/22

## BALANCE SHEET

for the period ended 31 march 2010

Period

01.01.2010.  
31.03.2010.

( LB currency EUR rate = 0.702804 )

ASSETS		Line code	The end of reporting period 2010.g. 01.01.- 31.03. LVL	The end of reporting period 2010.g. 01.01.- 31.03. EUR	The end of reporting period 2009.g. 01.01.- 31.03. LVL	The end of reporting period 2009.g. 01.01.- 31.03. EUR
<b>1. Long - term investments</b>						
<i>I Intangible investments</i>						
1 Research and development costs		10				
2 Concessions, patents, licenses, trade-marks and similar rights		20	51 930	73 890	52 766	75 079
3 Other intangible rights		21				
4 Intangible value of enterprise		30	-	-	-	-
5 Advance payments of intangible investments		40				
<b>TOTALLY</b>	<b>1</b>		<b>51930</b>	<b>73890</b>	<b>52766</b>	<b>75079</b>
<i>II Fixed assets</i>						
1 Lands, buildings, constructions and preennial plantations		60	455 201	647 693	492 127	700 234
2 Long-term leased fixed		70				
3 Technological equipment and machines		80	175 095	249 138	200 773	285 674
4 Other fixed assets and inventory		90	58 329	82 995	76 871	109 378
5 Forming of fixed assets and costs of unfinished objects of constructio		100				
6 Advance payments for fixed assets		110				
<b>TOTALLY</b>	<b>2</b>		<b>688625</b>	<b>979825</b>	<b>769771</b>	<b>1095285</b>
<i>III Long - term financial investments</i>						
1 Participation in capital of related companies		130				
2 Loans to related companies		140				
3 Participation in capital of affiliated companies		150				
4 Loans to affiliated companies		160				
5 Other securities and investments		170				
6 Other loans		180				
7 Own stocks and shares		190				
8 Loans to joint owners and administration		200				
<b>TOTALLY</b>			<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>
<b>1. TOTALLY</b>			<b>740555</b>	<b>1053715</b>	<b>822537</b>	<b>1170365</b>
<b>2. Current assets</b>						
<i>I Stocks</i>						
1 Row materials, direct materials and auxiliary materials	<b>3</b>	230	277 656	395 069	260 650	370 872
2 Unfinished products	<b>4</b>	240	5 693	8 100	41 071	58 439
3 Complete products and goods for sale	<b>5</b>	250	136 610	194 379	111 743	158 996
4 Unfinished orders		260				
5 Advance payments for goods	<b>6</b>	270	11 946	16 998	1 346	1 915
6 Work animals and productive animals	<b>7</b>	280	150	213	150	213
<b>TOTALLY</b>			<b>432055</b>	<b>614759</b>	<b>414960</b>	<b>590435</b>
<i>II Debtors</i>						
1 Customers and client debts	<b>8</b>	300	104 965	149 352	28 613	40 713
2 Related companies debts		310	-		-	
3 Affiliated companies debts		320	-		-	
4 Other debts	<b>9</b>	330	118 401	168 469	238 929	339 965
5 Undeposited shares in business capital		340				
6 Short - term loans to joint owners and administration	<b>9</b>	350	151	215	420	598
7 Accrued income	<b>10</b>	360	2 503	3 561	8 181	11 641
<b>TOTALLY</b>			<b>226020</b>	<b>321597</b>	<b>276143</b>	<b>392916</b>
<i>III Securities and participation in capitals</i>						
1 Participation in capital of related companies		380				
2 Own stocks and shares		390				
3 Other securities and participation in capitals		400				
<b>TOTALLY</b>			<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>
<i>IV Cash assets (TOTAL)</i>						
1 Cash assets	<b>11</b>	420	5 390	7 669	4 481	6 376
<b>2. TOTALLY</b>			<b>663465</b>	<b>944026</b>	<b>695584</b>	<b>989727</b>
<b>BALANCE</b>			<b>1404020</b>	<b>1997740</b>	<b>1518121</b>	<b>2160092</b>

LIABILITIES		Line code	The end of reporting period 2010.g. 01.01.- 31.03. LVL	The end of reporting period 2010g. 01.01.- 31.03. EUR	The end of reporting period 2009.g. 01.01.- 31.03. LVL	The end of reporting period 2009.g. 01.01.- 31.03. EUR
<b>1. Equity capital</b>						
<i>Equity capital</i>						
1 Stock or share capital (equity capital)	12	450	663 000	943 364	663 000	943 364
2 Stock issue extra charge		460	-		-	
3 Long - term investment re-estimation reserve		470	-		-	
4 Prescribed reserves		480	-		-	
5 Reserves for own stocks and shares		490	-		-	
6 Reserves prescribed by enterprise		500	-		-	
7 Other reserves		510	28 060	39 926	28 060	39 926
8 Retained profit of previous years		530	(244 544)	(347 955)	739 748	1 052 567
9 Retained profit of the year of accountant	23	540	69 064	98 269	21 722	30 908
<b>TOTALLY</b>			<b>515580</b>	<b>733604</b>	<b>1452530</b>	<b>2066764</b>
<b>1. TOTALLY</b>			<b>515580</b>	<b>733604</b>	<b>1452530</b>	<b>2066764</b>
<b>2. Stockpiles</b>						
<i>Stockpiles</i>						
1 Reserves for pensions and similar obligations		560				
2 Reserve for prospective taxes	13	570	41 829	59 517	36 103	51 370
3 Other stockpiles	13	580	11 102	15 797	21 454	30 526
<b>TOTALLY</b>			<b>52931</b>	<b>75314</b>	<b>57557</b>	<b>81896</b>
<b>2. TOTALLY</b>			<b>52931</b>	<b>75314</b>	<b>57557</b>	<b>81896</b>
<b>3. Creditors</b>						
<i>I Long - term debts</i>						
1 Funded borrowings		600	-		-	
2 Borrowings for shares		610	-		-	
3 Bank borrowings		620	-		-	
4 Other borrowings		630	-		-	
5 Customers advanced payments		640	-		-	
6 Debts to suppliers and contractors		650	-		-	
7 Bills to be paid		660	-		-	
8 Borrowings from related companies		670	-		-	
9 Borrowings from affiliated companies		680	-		-	
10 Tax and social security payments		690	-		-	
11 Other creditors	14	700	-		-	
12 Deferred income		710	-		-	
13 Dividends of the year of account		720	-		-	
14 Unpaid dividends of previous years		730	-		-	
<b>TOTALLY</b>			<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>
<i>II Short - term debts</i>						
1 Funded borrowings		750	-		-	
2 Borrowings for shares		760	-		-	
3 Bank borrowings		770	-		-	
4 Other borrowings		780	-		-	
5 Customers advanced payments	14	790	585 000	832 380	-	
6 Debts to suppliers and contractors	14	800	224 993	320 136	35 343	50 289
7 Bills to be paid		810	-		-	
8 Borrowings from related companies		820	-		-	
9 Borrowings from affiliated companies		830	-		-	
10 Tax and social security payments	14	840	14 192	20 193	(42 618)	(60 640)
11 Other creditors	14	850	11 324	16 113	15 309	21 783
12 Deferred income		860	-		-	
13 Dividends of the year of account		870	-		-	
14 Unpaid dividends of previous years		880	-		-	
<b>TOTALLY</b>			<b>835509</b>	<b>1188822</b>	<b>8034</b>	<b>11431</b>
<b>3. TOTALLY</b>			<b>835509</b>	<b>1188822</b>	<b>8034</b>	<b>11431</b>
<b>BALANCE</b>			<b>1404020</b>	<b>1997740</b>	<b>1518121</b>	<b>2160092</b>

# a/s "Rīgas Farmaceutiskā Fabrika "

reg. No 40003000765  
Rīga, Dunties iela 16/22

## PROFIT OR LOSS STATEMENT

for the period ended 31 march 2010

Period 01.01.2010.  
31.03.2010.

( LB currency EUR rate = 0.702804 )

No	Special rate	Note	ROW	The end of reporting period 2010.g. 01.01.-31.03. LVL	The end of reporting period 2010.g. 01.01.-31.03. EUR	The end of reporting period 2009.g. 01.01.-31.03. LVL	The end of reporting period 2009.g. 01.01.-31.03. EUR
1.	Net turnover	15	10	717645	1021117	637791	907495
2.	Cost of sales (prime cost)	16	20	-419265	-596560	-399848	-568932
3.	Gross profit or loss		30	298380	424556	237943	338562
4.	Sales Distribution costs:	16	40	-96753	-137667	-86775	-123470
5.	Administration costs	16	50	-129005	-183558	-111539	-158706
6.	Other operating income	17	60	314	447	158	225
7.	Other operating expenses	18	70	-3003	-4273	-3368	-4792
8.	Income from participation in capital of related and affiliated companies		80				
9.	Income from securities and long - term loans		90				
10.	Other interests receivable and similar income		100				
11.	Amounts written off investments		110				
12.	Interest payable and similar changes		120				
13.	Profit or loss before extraordinary items and tax	19	130	69933	99506	36419	51820
14.	Extraordinary income		140				
15.	Extraordinary charges		150				
16.	Profit or loss before tax	19	160	69933	99506	36419	51820
17.	Tax on profit or loss for the financial period	20	170	0	0	-13882	-19752
18.	Tax on profit (pustpone) or loss for the financial period	21	170	0	0	0	0
19.	Other taxes	22	180	-869	-1236	-815	-1160
20.	Profit or loss for the financial period	23	190	69064	98269	21722	30908
EPS k-t				0,104	0,148	0,033	0,047

Enterprise name

**RĪGAS FARMACEITISKĀ FABRIKA A/S**

Registration No

**0 0 0 3 0 0 0 7 6**

Registration No of tax-payer

**4 0 0 0 3 0 0 0 7 6 5**Address **Rīga , Duntes iela 16/22**Phone **67355550, 67355548** Fax **67391790**Unit: **LVL and EUR****OVERVIEW OF EQUITY CAPITAL CHANGES**

				Period	
		( LB currency EUR rate = 0.702804 )		01.01.2010.	31.03.2010.
		for the period ended 31 march 2010			
		The end of reporting period 2010.g. 01.01.- 31.03. , LVL	The end of reporting period 2010.g. 01.01.- 31.03. , EUR	The end of reporting period 2009.g. 01.01.- 31.03. , LVL	The end of reporting period 2009.g. 01.01.- 31.03. , EUR
<b>1.</b>	<b>Share capital</b>				
	Post-balance residue on: 01.01.2010.	663 000	943 364	663 000	943 364
	Increase :	0	0	0	0
	Decrease :	0	0	0	0
	Post-balance residue on: 31.03.2010.	663 000	943 364	663 000	943 364
<b>2.</b>	<b>Share premium</b>				
	Post-balance residue on: 01.01.2010.	0	0	0	0
	Increase :	0	0	0	0
	Decrease :	0	0	0	0
	Post-balance residue on: 31.03.2010.	0	0	0	0
<b>3.</b>	<b>Revaluation reserve of long-term investments</b>				
	Post-balance residue on: 01.01.2010.	0	0	0	0
	Increase :	0	0	0	0
	Decrease :	0	0	0	0
	Post-balance residue on: 31.03.2010.	0	0	0	0
<b>4.</b>	<b>Mandatory reserves</b>				
	Post-balance residue on: 01.01.2010.	0	0	0	0
	Increase :	0	0	0	0
	Decrease :	0	0	0	0
	Post-balance residue on: 31.03.2010.	0	0	0	0
<b>5.</b>	<b>Revaluation of own stocks of shares reserves</b>				
	Post-balance residue on: 01.01.2010.	0	0	0	0
	Increase :	0	0	0	0
	Decrease :	0	0	0	0
	Post-balance residue on: 31.03.2010.	0	0	0	0
<b>6.</b>	<b>Reserves determined by company statute</b>				
	Post-balance residue on: 01.01.2010.	0	0	0	0
	Increase :	0	0	0	0
	Decrease :	0	0	0	0
	Post-balance residue on: 31.03.2010.	0	0	0	0
<b>7.</b>	<b>Other reserves</b>				
	Post-balance residue on: 01.01.2010.	28 060	39 926	28 060	39 926
	Increase :	0	0	0	0
	Decrease :	0	0	0	0
	Post-balance residue on: 31.03.2010.	28 060	39 926	28 060	39 926
<b>8.</b>	<b>Retained profit</b>				
	Post-balance residue on: 01.01.2010.	-244 544	-347 955	739 748	1 052 567
	Post-balance residue on: 31.03.2010.	-175 480	-249 686	761 470	1 083 474
<b>9.</b>	<b>Equity capital (total)</b>				
	Post-balance residue on: 01.01.2010.	<b>446 516</b>	<b>635 335</b>	<b>1 430 808</b>	<b>2 035 856</b>
	Post-balance residue on: 31.03.2010.	<b>515 580</b>	<b>733 604</b>	<b>1 452 530</b>	<b>2 066 764</b>

# a/s "Rīgas Farmaceutiskā Fabrika "

reg. No 40003000765

Rīga , Dunties iela 16/22

## STATEMENT OF CASH FLOW

for the period ended 31 march 2010

Period 01.01.2010.

(LB currency EUR rate = 0.702804) 31.03.2010.

	Note No	The end of reporting period 2010.g. 01.01.-31.03. , LVL	The end of reporting period 2010.g. 01.01.-31.03. , EUR	The end of reporting period 2009.g. 01.01.-31.03. , LVL	The end of reporting period 2009.g. 01.01.-31.03. , EUR
<b>CASH FLOW from operating activities</b>					
Net profit (before enterprise income tax)		69933	99506	36419	51820
<i>Corrections to adjust the profit of revision year to hard cash of economic activities :</i>					
Depreciation of fixed assets and intangible investments		34778	49485	56676	80643
Profit or loss from sale of fixed assets and intangible investments		0	0	-6964	-9909
Expenditures per cent		0	0	0	0
Provisions for non-used holidays		-2899	-4125	-2822	-4015
Other reserves		0	0	0	0
Debt expenditures of doubtful debtors		0	0	0	0
Incoming of next periods		0	0	0	0
The taxes to deduct from net profit (property tax)		-869	-1236	-815	-1160
Paid enterprise income tax		0	0	-13882	-19752
<i>The changes of the current assets and liabilities:</i>					
Provisions		3248	4621	21822	31050
Debts of customers and subscribers		94742	134806	156295	222388
Expenditures of next periods		3411	4853	-1392	-1981
Others debtors		79101	112551	281448	400464
Advance payments from customers		120000	170745	0	0
Debts to suppliers and contractors		-372080	-529422	-453517	-645297
Other creditors		-2452	-3489	-45527	-64779
<b>Net cash provided by (used in) operating activities</b>		<b>26913</b>	<b>38294</b>	<b>27741</b>	<b>39472</b>
<b>CASH FLOW from investing activities</b>					
Fixed assets purchase costs		-33205	-47246	-24063	-34239
Investment costs		0	0	0	0
Fixed assets selling income		0	0	0	0
Investment selling income		0	0	0	0
Company equity		0	0	0	0
Dividends received		0	0	0	0
<b>Net cash provided by (used in) investing activities</b>		<b>-33205</b>	<b>-47246</b>	<b>-24063</b>	<b>-34239</b>
<b>CASH FLOW from financing activities</b>					
Income from issue		0	0	0	0
Loans from credit institutions		0	0	0	0
Loans to creditors		0	0	0	0
Payments for leasing liabilities		0	0	0	0
Other loans		0	0	0	0
Fixed assets investments		0	0	0	0
Cost of dividends		0	0	0	0
<b>Net cash provided by (used in) financing activities</b>		<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>
<b>Net increase (decrease) in cash</b>		<b>-6292</b>	<b>-8953</b>	<b>3678</b>	<b>5233</b>
<b>Cash at the beginning of the year</b>		<b>11682</b>	<b>16622</b>	<b>803</b>	<b>1143</b>
<b>Cash at the end of the year</b>		<b>5390</b>	<b>7669</b>	<b>4481</b>	<b>6376</b>

A/S " RĪGAS FARMACEITISKĀ FABRIKA "

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 March 2010

ACCOUNTING POLICES

(1) Basis of preparation

The financial statements have been prepared in accordance with general accounting principles that correspond to the laws of the Republic of Latvia. All amounts presented in these financial statements are denominated in EUR of the Bank of Latvia LVL rate of exchange as at date of report (0,702804).

The financial statements reporting period is from 01 January 2010 till 31 March 2010.

The company's accounting policies have not changed in comparison with the previous year.

The financial statements reporting period is not verified by auditor.

1. INTANGIBLE ASSETS

	Expenditures on research activities LVL / EUR	Licenses and patents LVL / EUR	Company's intangible value LVL / EUR	Total LVL / EUR
<b>Historical cost</b> as of 1 January 2010	0	94 152 / 133 966	3 682 / 5 239	97 834 / 139 205
Additions	0	4 280 / 6 090	0	4 280 / 6 090
Disposals	0	0 / 0	0	0 / 0
<b>Historical cost</b> as of 31 March 2010	0	98 432 / 140 056	3 682 / 5 239	102 114 / 145 295
Accumulated depreciation before 2010	0	43 269 / 61 566	3 682 / 5 239	46 951 / 66 805
Excluded on disposal	0	0	0	0 / 0
Accumulated depreciation in 2010	0	3 233 / 4 600	0	3 233 / 4 600
Net book value as of 31 March 2010	0	51 930 / 73 890	0	51 930 / 73 890

2. FIXED ASSETS

	Land LVL / EUR	Buildings LVL / EUR	Equipmen t LVL / EUR	Computin g equipment LVL / EUR	Other fixed assets LVL / EUR	Pendin g objects LVL / EUR	Total LVL / EUR
<b>Historical cost</b> as of 1 January 2010	67 473 / 96 005	581 600 / 827 542	502 305 / 714 715	30 735 / 43 731	222 166 / 316 115	0	1 404 279 / 1 998 108
Additions	0	0	28 775 / 40 943	0	150 / 213	0	28 925 / 41 156
Disposals	0	0	0	0	0	0	0
<b>Historical cost</b> as of 31 March 2010	67 473 / 96 005	581 600 / 827 542	531 080 / 755 658	30 735 / 43 731	222 316 / 316 328	0	1 433 204 / 2 039 264
Accumulated depreciation before 2010	0	191 372 / 272 298	327 439 / 465 904	27 852 / 39 630	166 370 / 236 723	0	713 033 / 1 014 555
Accumulated depreciation in 2010	0	2 500 / 3 556	28 546 / 40 616	100 / 142	400 / 569	0	31 546 / 44 883
Excluded on disposal	0	0	0	0	0	0	0
Net book value as of 31 March 2010	67 473 / 96 005	387 728 / 551 688	175 095 / 249 138	2 783 / 3 959	55 546 / 79 036	0	688 625 / 979 825

### 3. RAW AND ANCILLARY MATERIALS

Raw and ancillary materials are presented at their historical cost .

### 4. GOODS FOR SALE

Goods for sale are presented in the financial statements at their net realizable value

### 5. GOODS HELD ON CONSIGNMENT

Goods held on consignment are presented in the financial statements at their net realizable value

### 6. ADVANCE PAYMENTS

Advance payments for following period expenses connected with real estate, amounts for raw and ancillary materials as well as advance payments for fixed assets are presented in advance payments.

7. Work animals – guard dog.

### 8. ACCOUNTS RECEIVABLE

All accounts receivable are short-term.

### 9. OTHER DEBTORS

	As of 31 March 2010 LVL / EUR	As of 01 January 2010 LVL / EUR
Corporate income tax overpayment	44 971 / 63 988	44 971 / 63 988
VAT overpayment	73 430 / 104 481	152 477 / 216 955
Other income overpayment	0 / 0	0 / 0
Short-term loans to partners and employees	151 / 215	205 / 292
Total	118 552 / 168 684	197 653 / 281 235

VAT overpayment and corporate income tax overpayment amount has been used to cover VAT and other taxes for 2010.Year.

### 10. DEFERRED EXPENSES

	As of 31 March 2010 LVL / EUR	As of 01 January 2010 LVL / EUR
Press subscription	479 / 682	479 / 682
Insurance	903 / 1 284	1 875 / 2 668
Other	1 121 / 1 595	3 560 / 5 065
Total	2 503 / 3 561	5 914 / 8 415

### 11. CASH

	As of 31 March 2010 LVL / EUR	As of 01 January 2010 LVL / EUR
Cash on hand	1 011 / 1 438	847 / 1 205
Current account with NORDEA BANKA (LVL)	664 / 945	8 857 / 12 602
Current account with HANSABANKA (LVL)	3 715 / 5 286	1 978 / 2 815
Current account with HANSABANKA (currency)	0	0
Total	5 390 / 7 669	11 682 / 16 622

### 12. SHARE CAPITAL

The share capital of the Company consisted of 663,000 LVL; that is 660,000 common voting shares and 3,000 common nonvoting shares with nominal value 1 LVL per share.



### 13. PROVISIONS

Provisions for the reporting year consisted of vacation salaries and other remaining balance amounts.

### 14. CREDITORS

	As of 31 March 2010 LVL / EUR	As of 01 January 2010 LVL / EUR
Customer s advanced payments	585 000 / 832 380	465 000 / 661 635
Debtor overpayment	0 / 0	263 793 / 375 344
Due to suppliers	224 993 / 320 136	333 280 / 474 215
Salary for December	11 324 / 16 113	13 455 / 19 145
Taxes and social security payment	14 192 / 20 193	14 513 / 20 650
Corporate income tax	0 / 0	0 / 0
Total	835 509 / 1 188 822	1 090 041 / 1 550 989

### 15. SALES

	LVL / EUR
Total sales	717 645 / 1 021 117
including : - operating income	703 129 / 1 000 462
- other operating expenses	14 516 / 20 655

### 16. SALES EXPENSES

Production expenses	419 265 / 596 560
Sales expenses	96 753 / 137 667
Administrative expenses	129 005 / 183 558
Total expenses	645 023 / 917 785
Profit or Loss for the year	72 622 / 103 332

### 17. OTHER OPERATING INCOME

Bank interest for application of funds from current account	0 / 0
Income from currency fluctuations	45 / 64
Other	269 / 383
Total	314 / 447

### 18. OTHER OPERATING EXPENSES

Interest payments (leasing)	1 037 / 1 476
Expenses from currency fluctuations	1 715 / 2 440
Fines paid	3 / 4
Provisions for vacations	0 / 0
Donations	3 / 4
Previous periods expenses that are included in current statement	0 / 0
Other	245 / 349
Total expenses	3 003 / 4 273

<b>19. PROFIT OR LOSS FOR THE YEAR BEFORE TAX</b>	69 933 / 99 506
---	-----------------

<b>20. CORPORATE INCOME TAX</b> ( advance payments )	0 / 0
<b>21. CORPORATE INCOME TAX</b> /postpone/	0 / 0

<b>22. OTHER TAXES</b>	869 / 1 237
------------------------	-------------

<b>23. NET PROFIT OR LOSS</b>	69 064 / 98 269
-------------------------------	-----------------

24. The average number of employees in 2009 was 63.

**A/S "RĪGAS FARMACEITISKĀ FABRIKA"  
GOVERNING BODY REPORT**

JSC "Riga Pharmaceutical Plant" is situated in Riga, 16/22 Dantes street and 6 Maza Ozolu street. The enterprise is the largest producer of finite pharmaceuticals, medical plants and drugs in Latvia. The factory was registered in Latvian Commercial Register of Enterprises in 2004. The Company has the licence for opening (activity) of drug manufacturing enterprise and has successfully passed the GMP certificate, as well as ISO 14001 standard.

The main business course of the enterprise is devoted to the manufacturing of medicines, medical goods and food supplements. All kinds of produced medicines are being realized in Latvia.

In first 3 months of 2010 the enterprise turnover was 1 021 117 EUR (717 645 LVL), which is about 12 % more than in a corresponding period in 2009. The income of the enterprise in first 3 months of 2010 was 98 269 EUR (69 064 LVL), which is more than in a corresponding period of 2009.

The government of JSC "Riga Pharmaceutical Plant" (later in the text - Enterprise) is responsible for the preparing of intermediate finance report. Intermediate reports of the enterprise are not being audited. This management report based on accountant abstracts and incoming documents is considered to provide real and true information about the assets, liabilities and the whole financial position of the enterprise.

The government of the enterprise is responsible for using a corresponding register system, for preservation of assets of the enterprise and for investigation and elimination of the deceptions and delusions committed by the enterprise. The government of the enterprise is also responsible for the observance of Latvian legislation.